AlphaGenome 2: Deciphering how cells read DNA to better understand
November 11, 2026 Science AlphaGenome 2: Deciphering how cells read DNA to better understand disease Adam Gayoso, Natasha Latysheva, Pushmeet Kohli and Žiga…
Summary
November 11, 2026 Science AlphaGenome 2: Deciphering how cells read DNA to better understand disease Adam Gayoso, Natasha Latysheva, Pushmeet Kohli and Žiga Avsec Read the paper Share Our next-generation DNA sequence model bridges single-cell biology and human genetics, predicting how genetic variants affect hundreds of human cell types. Today, we are announcing AlphaGenome 2, our next-generation model that predicts how DNA sequences and their variations impact specific human cell types, giving scientists a powerful new tool to uncover the cellular drivers of disease. Every cell in our body carries the same DNA blueprint, yet each cell type and state—like a heart muscle cell or an immune cell fighting an infection—switches different genes on or off to do its job. Global efforts like the Human Cell Atlas are mapping this gene expression for millions of cells, but it is still an unsolved challenge to predict how subtle DNA variations affect this expression in cells, which is a key driver of human traits and disease.
Positives
- Last year, we launched AlphaGenome to predict how DNA variants affect molecular activity across broad tissues.
- We expanded its reach with AlphaGenome Atlas, a platform containing predictions for all 9 billion possible single-letter changes in the human genome.
- These tools help researchers prioritize and interpret variant effects, driving discoveries in rare diseases, complex traits, and fundamental biology.
Risks & concerns
- The article may not provide enough evidence to validate every implication.
- Execution, cost, adoption, regulation, or security could change the outcome.